As filed with the Securities and
Exchange Commission on June 4, 2024
No. 333-257653
No. 333-270604
No. 333-272713
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective Amendment No. 1
to:
FORM S-3 REGISTRATION STATEMENT No. 333-257653
FORM S-3 REGISTRATION STATEMENT No. 333-270604
FORM S-3 REGISTRATION STATEMENT No. 333-272713
UNDER
THE SECURITIES ACT OF 1933
Fusion
Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
| Canada |
|
Not applicable |
(State or other jurisdiction of
incorporation or organization) |
|
(IRS Employer
Identification No.) |
270 Longwood Road South
Hamilton, Ontario, Canada, L8P 0A6
(Address of principal executive offices, including zip code)
(289) 799-0891
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Maria Stahl
Chief Legal
Officer
Fusion Pharmaceuticals Inc.
Two International Place, Suite 2310
Boston, Massachusetts 02110
(617) 420-5698
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Sebastian L. Fain
Oliver
J. Board
Freshfields Bruckhaus Deringer US LLP
3 World Trade Center
175
Greenwich Street
New York, NY 10007
(212) 277-4000
Approximate date of
commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is
a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
| Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
| Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐